PARIS — Persistent questions on whether rare but serious blood clots among those getting the AstraZeneca jab against Covid-19 are more frequent than in the general population, and what causes them if they are, have continued to undermine confidence in the beleaguered vaccine.
The European Medicines Agency — which has said that benefits outweigh risks such that the vaccine should remain in use — will provide an updated assessment next week.
What has been observed?
The blood clots seen in a handful of people vaccinated with AstraZeneca are described by the French Medicines Agency (ANSM) as “highly untypical”.
“This thrombosis of large veins is unusually located in the brain, an…
Keep on reading: Questions about AstraZeneca jab linger